Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2010

01-12-2010 | Original Paper

Decreased expression of KLF6 and its significance in gastric carcinoma

Authors: Qing Zhang, Xiao-ping Tan, Yue-sha Yuan, Cheng-ming Hu, Chang-hua He, Wei-zheng Wang, Jun-chuan Li, Qiu Zhao, Nan-zhi Liu

Published in: Medical Oncology | Issue 4/2010

Login to get access

Abstract

To study the expression of the Krüppel-like transcription factor 6 (KLF6) in human gastric carcinoma and normal gastric mucosa tissues, and to explore the role of KLF6 in the carcinogenesis and tumor progression and its clinical significance. Expression of KLF6, P21WAF1 and PCNA was investigated by immunohistochemistry for 69 surgically resected gastric carcinoma tissues and corresponding normal gastric mucosa tissues, respectively. The correlations of KLF6 expression with clinicopathological characteristics, P21WAF1 and PCNA were examined. Positive-expression of KLF6 was 64 out of 69 cases (92.8%) in normal gastric mucosa and only 23 cases (33.3%) in gastric carcinoma. Expression of KLF6 in the gastric carcinoma was remarkably lower than normal gastric mucosa. Decreased expression of KLF6 in gastric carcinoma was significantly associated with histological differentiation (P < 0.01), TNM stage (P < 0.05), lymph node metastasis (P < 0.01) and distant metastasis (P < 0.05). There was no significant correlation between KLF6 expression and sex, age. Meanwhile, expression of KLF6 was associated with expression of P21WAF1 in both normal gastric mucosa and gastric carcinoma (P < 0.05). In addition, decreased expression of KLF6 in gastric carcinoma was positively associated with PCNA level (r = 0.719, P < 0.01) by association analysis. Down-regulation of KLF6 might play an important role in the carcinogenesis and development of human gastric carcinoma and have significant clinical value.
Literature
1.
2.
Kobayashi T, Kikuchi S, Lin Y, et al. Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy. Gastric Cancer. 2004;7(4):233–9.PubMedCrossRef
3.
Anderson KP, Kern CB, Crable SC, Lingrel JB. Isolation of a gene encoding a functional zinc finger protein homologous to erythroid Kruppel-like factor: identification of a new multigene family. Mol Cell Biol. 1995;15:5957–65.PubMed
4.
Black AR, Black JD, Azizkhan-Clifford J. Sp1 and Kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol. 2001;188:143–60.PubMedCrossRef
5.
Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW. Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett. 2000;476:203–7.PubMedCrossRef
6.
Girard L, Zo¨chbauer-Mu¨ller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res. 2000;60:4894–906.PubMed
7.
Narla G, Heath KE, Reeves HL, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science. 2001;294:2563–6.PubMedCrossRef
8.
Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, et al. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res. 2004;64:3885–91.PubMedCrossRef
9.
Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL. A new role for the kruppel-like transcription factor KLF6 as an inhibitor of c-jun proto-oncoprotein function. Oncogene. 2004;23:8196–205.PubMedCrossRef
10.
Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S, et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology. 2004;126:1090–103.PubMedCrossRef
11.
Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A, et al. Frequent inactivation of the tumor suppressor kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology. 2004;40:1047–52.PubMedCrossRef
12.
DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, et al. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res. 2006;12:3730–9.PubMedCrossRef
13.
Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, et al. Kruppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells. Cancer Res. 2004;64:3838–43.PubMedCrossRef
14.
Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002;2:485–95.PubMedCrossRef
15.
Jeng YM, Hsu HC. KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas. Int J Oncol. 2003;105:625–9.
16.
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 2005;65:1213–22.PubMedCrossRef
17.
Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, et al. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res. 2005;65:5761–8.PubMedCrossRef
18.
Kimmelman AC, Qiao RF, Narla G, Banno A, Lau N, Bos PD, et al. Suppression of glioblastoma tumorigenicity by the kruppel-like transcription factor KLF6. Oncogene. 2004;23:5077–83.PubMedCrossRef
19.
Chen C, Hyytinen ER, Helin HJ, Koivisto PA, Frierson HF Jr, Vessella RL, et al. Deletion mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol. 2003;162:1349–54.PubMed
20.
21.
Cho YG, Kim CJ, Park CH, Yang YM, Kim SY, Nam SW, et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene. 2005;24(28):4588–90.PubMedCrossRef
22.
Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, et al. Functional role of the KLF6 tumour suppressor gene in gastric cancer. Eur J Cancer. 2009;45(4):666–76. Epub 2008 Dec 26.PubMedCrossRef
23.
Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K, et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene. 2007;26(30):4428–34. Epub 2007 Feb 5.PubMedCrossRef
24.
Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, et al. KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma. Int J Cancer. 2007;121(9):1976–83.PubMedCrossRef
25.
Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY. Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B. 2006;7(10):830–6.PubMedCrossRef
26.
Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, et al. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. Int J Cancer. 2007;121(6):1390–5.PubMedCrossRef
27.
Kim JS, Lee S, Lee T, Lee YW, Trepel JB. Transcriptional activation of p21 (WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun. 2001;281:866–71.PubMedCrossRef
28.
Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, el-Houseini ME. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 1994;9:3389–96.PubMed
29.
Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21WAF1 regulation. World J Gastroenterol. 2002;8:400–5.PubMed
30.
31.
Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, et al. Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002;21:5804–13.PubMedCrossRef
32.
DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat. 2009;12(1–2):1–7. Epub 2008 Dec 18.PubMedCrossRef
Metadata
Title
Decreased expression of KLF6 and its significance in gastric carcinoma
Authors
Qing Zhang
Xiao-ping Tan
Yue-sha Yuan
Cheng-ming Hu
Chang-hua He
Wei-zheng Wang
Jun-chuan Li
Qiu Zhao
Nan-zhi Liu
Publication date
01-12-2010
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2010
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-009-9377-7

Other articles of this Issue 4/2010

Medical Oncology 4/2010 Go to the issue

Original Paper

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment

Original Paper

Association between EGF promoter polymorphisms and cancer risk: a meta-analysis

Case Report

Intracystic papillary carcinoma of the breast: one of the youngest patient in the literature

Original Paper

The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater

Original Paper

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

Letter to the Editor

Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits